Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Upstream Processing01:27

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Separation of Monoclonal Antibody Aggregates Using an Analytical Ultrafiltration Technique.

Membranes·2026
Same author

Localizing the Glycan Binding Sites of SARS-CoV-2 Receptor-Binding Domain.

Analytical chemistry·2026
Same author

British Association of Sexual Health and HIV guidelines on the management of viral hepatitis 2026.

International journal of STD & AIDS·2026
Same author

Ectopic pregnancy outcomes in the emergency department: a review of delays to diagnostic ultrasound.

CJEM·2026
Same author

CHO Cell Line Selection through Multi-Criteria Analysis Reveals Critical Impact of Gas Overlay.

Biotechnology journal·2026
Same author

Durability of DNA-LNP and mRNA-LNP vaccine-induced immunity against SARS-CoV-2 XBB.1.5.

NPJ vaccines·2026

Related Experiment Video

Updated: Jun 19, 2026

High Yield Expression of Recombinant Human Proteins with the Transient Transfection of HEK293 Cells in Suspension
11:42

High Yield Expression of Recombinant Human Proteins with the Transient Transfection of HEK293 Cells in Suspension

Published on: December 28, 2015

Expression systems for therapeutic glycoprotein production.

Yves Durocher1, Michael Butler

  • 1Animal Cell Technology Group, Biotechnology Research Institute, National Research Council Canada, 6100 Royalmount Avenue, Montreal (QC) H4P2R2, Canada. yves.durocher@nrc-cnrc.gc.ca

Current Opinion in Biotechnology
|November 6, 2009
PubMed
Summary

The demand for high-quality glycoproteins in medicine is rising, driving innovation in cell culture and expression systems for efficient biopharmaceutical manufacturing. Advances in Chinese hamster ovary (CHO) cells and glycoengineering enhance therapeutic protein production.

More Related Videos

A Convenient and General Expression Platform for the Production of Secreted Proteins from Human Cells
07:09

A Convenient and General Expression Platform for the Production of Secreted Proteins from Human Cells

Published on: July 31, 2012

Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells
06:53

Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells

Published on: June 2, 2022

Related Experiment Videos

Last Updated: Jun 19, 2026

High Yield Expression of Recombinant Human Proteins with the Transient Transfection of HEK293 Cells in Suspension
11:42

High Yield Expression of Recombinant Human Proteins with the Transient Transfection of HEK293 Cells in Suspension

Published on: December 28, 2015

A Convenient and General Expression Platform for the Production of Secreted Proteins from Human Cells
07:09

A Convenient and General Expression Platform for the Production of Secreted Proteins from Human Cells

Published on: July 31, 2012

Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells
06:53

Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells

Published on: June 2, 2022

Area of Science:

  • Biotechnology
  • Biopharmaceutical Manufacturing
  • Protein Engineering

Background:

  • Over 165 recombinant pharmaceuticals are approved, with 500 more in development, 70% being glycoproteins.
  • Efficient manufacturing of high-quality glycoproteins is crucial for meeting therapeutic demands.

Purpose of the Study:

  • To review advancements in expression systems for glycoprotein manufacturing.
  • To highlight strategies for improving the efficiency and quality of therapeutic protein production.

Main Methods:

  • Focus on Chinese hamster ovary (CHO) cells, the primary mammalian expression system.
  • Discusses glycoengineering strategies and alternative expression systems.
  • Highlights methods for increasing cell specific productivity and lifespan for high integrated viable cell densities.

Main Results:

  • CHO cell advancements have led to volumetric productivities exceeding 5 g/L with controlled nutrient feeding.
  • Glycoengineering offers enhanced therapeutic properties for proteins.
  • Alternative expression systems are under development with varying pros and cons.

Conclusions:

  • Continued innovation in expression systems, particularly CHO cells and glycoengineering, is essential for advancing glycoprotein-based therapeutics.
  • Optimizing manufacturing processes is key to producing high-quality, effective biopharmaceuticals.